Patients on ClopidogrelNCT07600060
Frequency of Platelets Transfusion & Post-Operative Bleeding Risk in Patients on Clopidogrel Undergoing CABG
An observational study of Patients on Clopidogrel and Platelets Transfusion, run by Aga Khan University at 1 site in Pakistan.
Trial summary
The goal of this retrospective cohort study Is to Primarily be platelet transfusion frequency and postoperative bleeding risk, analysis using descriptive and inferential statistics in all eligible patients admitted to the cardiac intensive care unit (CICU) for open-heart surgery were included of both gender, age group… Read more about this study
- Who is it for?
- Ages 30 to 80 years
- Conditions the study is for
- Patients on Clopidogrel, Platelets Transfusion
- How many people
- 227 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jul 2022to 30 Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All eligible patients admitted to the cardiac intensive care unit (CICU) for open-heart surgery were included.
Who may be able to join
- CICU patients who underwent cardiac surgery
- Adults aged 30-80 years undergoing cardiac surgery with cardiopulmonary bypass
- Patients who received dual antiplatelet therapy, last dose within 5 days before surgery
Who cannot join
- BMI > 40 kg/m²
- Repeat open-heart surgery (reoperation)
- Transferred open-chest procedures
- Active liver disease
- Chronic lung disease
- Dialysis dependence
Show all 9Show fewer
- Intra-aortic balloon pump (IABP) in place pre- or post-operatively
- Major neurological deficit within the past 6 months
- Incomplete clinical records
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Frequency of Platelets Transfusion and Post-Operative Bleeding Risk in Patients on Clopidogrel Undergoing Coronary Artery Bypass Grafting (CABG): A Retrospective Cohort
The goal of this retrospective cohort study Is to Primarily be platelet transfusion frequency and postoperative bleeding risk, analysis using descriptive and inferential statistics in all eligible patients admitted to the cardiac intensive care unit (CICU) for open-heart surgery were included of both gender, age group of 30-80 years. The main questions it aims to answer are:
- How was the frequency of platelet transfusion during the index admission evaluated?
- How was post-operative bleeding risk measured?
- What does 24-hour chest drain output indicate in this context?
- How was packed cell volume (PCV) transfusion used as an outcome measure?
Read the detailed description
The Cardiac Intensive Care Unit (CICU) at a tertiary care facility in Karachi, Pakistan, served as the site of this retrospective cohort study. Every procedure adhered to institutional policies, and safe data management and de-identification preserved confidentiality. Consecutive sampling was employed due to the retrospective methodology, and the sample included all eligible CICU patients who had heart surgery during the study period. The study included patients on dual antiplatelet treatment (DAPT: aspirin and/or clopidogrel) with the last dose within five days before to surgery, as well as adults between the ages of thirty and eighty undergoing heart surgery with cardiopulmonary bypass (CPB).
- Conditions
- Patients on Clopidogrel, Platelets Transfusion
- Keywords
- Post-Operative Bleeding Risk in Patients
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of platelet transfusion
The frequency of platelet transfusion during the hospital stay.
Measured: From the day 1 of admission till discharge or 30 days of admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2026
- Study start1 Jul 2022
- Primary completion31 May 2023
- Study completion30 Jun 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patients on ClopidogrelStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 227 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aga Khan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Khalid Siddiqui, Aga Khan University
- Investigators
- Khalid Siddiqui, MBBS-FCPS, Principal investigator, Aga Khan UniversityKhalid Siddiqui, Principal investigator, Aga Khan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07600060
- Sponsor's protocol ID
- 2023-9576-27366
- Status last verified
- May 2026
- First submitted
- 25 Mar 2026
- Last updated
- 20 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Frequency of Platelets Transfusion and Post-Operative Bleeding Risk in Patients on Clopidogrel Undergoing Coronary Artery Bypass Grafting (CABG): A Retrospective Cohort
- ClinicalTrials.gov ID
- NCT07600060
- Acronym / sponsor ID
- 2023-9576-27366
- Conditions
- Patients on Clopidogrel, Platelets Transfusion
- Keywords
- Post-Operative Bleeding Risk in Patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 227 participants (actual)
- Lead sponsor
- Aga Khan UniversityUniversity, hospital or other
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 31 May 2023 (actual)
- Study completion
- 30 Jun 2023 (actual)
- First posted
- 20 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective cohort study Is to Primarily be platelet transfusion frequency and postoperative bleeding risk, analysis using descriptive and inferential statistics in all eligible patients admitted to the cardiac intensive care unit (CICU) for open-heart surgery were included of both gender, age group of 30-80 years. The main questions it aims to answer are:
- How was the frequency of platelet transfusion during the index admission evaluated?
- How was post-operative bleeding risk measured?
- What does 24-hour chest drain output indicate in this context?
- How was packed cell volume (PCV) transfusion used as an outcome measure?
Detailed description
The Cardiac Intensive Care Unit (CICU) at a tertiary care facility in Karachi, Pakistan, served as the site of this retrospective cohort study. Every procedure adhered to institutional policies, and safe data management and de-identification preserved confidentiality. Consecutive sampling was employed due to the retrospective methodology, and the sample included all eligible CICU patients who had heart surgery during the study period. The study included patients on dual antiplatelet treatment (DAPT: aspirin and/or clopidogrel) with the last dose within five days before to surgery, as well as adults between the ages of thirty and eighty undergoing heart surgery with cardiopulmonary bypass (CPB).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All eligible patients admitted to the cardiac intensive care unit (CICU) for open-heart surgery were included.
Key inclusion criteria (3 listed)
- CICU patients who underwent cardiac surgery
- Adults aged 30-80 years undergoing cardiac surgery with cardiopulmonary bypass
- Patients who received dual antiplatelet therapy, last dose within 5 days before surgery
Key exclusion criteria (9 listed)
- BMI > 40 kg/m²
- Repeat open-heart surgery (reoperation)
- Transferred open-chest procedures
- Active liver disease
- Chronic lung disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Frequency of platelet transfusion
Time frame: From the day 1 of admission till discharge or 30 days of admission
The frequency of platelet transfusion during the hospital stay.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 May 2026.
- Individual participant dataSharing planned: No
Related trials for Patients on Clopidogrel
RecruitingPhase 4
BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis
Stroke, Ischemic
Active, not recruitingPhase 4
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
RecruitingPhase 4
Clopidogrel Versus Cilostazol on Vessels
Type 2 Diabetes, Atherosclerosis
RecruitingPhase 4
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
Coronary Artery Disease
Not yet recruitingPhase 4
Impact of CYP2C19 Genotype-guided Approach in Antiplatelet Therapy on Platelet Reactivity Index Among Coronary Artery Disease (CAD) Patients
Coronary Arterial Disease (CAD), ACS (Acute Coronary Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Khalid Siddiqui, MBBS-FCPS principal investigator
Aga Khan University
Khalid Siddiqui principal investigator
Aga Khan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Patients on Clopidogrel and Platelets Transfusion, run by Aga Khan University at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of platelet transfusion (time frame: From the day 1 of admission till discharge or 30 days of admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 May 2026.